TGFB1 and chronic kidney disease: In contrast, Pirfenidone, which inhibits all three isoforms of TGF-β, resulted in improved eGFR in patients with pulmonary fibrosis [93]; current clinical trials using Pirfenidone to treat CKD are ongoing (NCT04258397).